tenecteplase + clopidogrel + enoxaparin

This is a **combination regimen** comprising three pharmacologically distinct agents: **tenecteplase** (a fibrinolytic), **clopidogrel** (a P2Y12 inhibitor antiplatelet), and **enoxaparin** (a low molecular weight heparin anticoagulant). This combination is used primarily for the acute management of **ST-elevation myocardial infarction (STEMI)** and other acute coronary syndromes. The regimen aims to restore vessel patency (tenecteplase, a tissue plasminogen activator analog promotes fibrinolysis), inhibit further platelet aggregation and thrombus growth (clopidogrel inhibits the P2Y12 receptor on platelets), and prevent new thrombus formation or extension (enoxaparin enhances inhibition of clotting factors, particularly factor Xa and IIa)[1][2][3]. Major trials and guidelines describe this combination as part of a pharmaco-invasive strategy in acute MI, where rapid reperfusion, prevention of re-occlusion, and reduction of major adverse cardiovascular events are key therapeutic goals.